How Long Will You Stay — on Sunitinib?

There is no standard answer that applies to every person. Duration depends on how your cancer responds, what your scans show at each assessment, and how well you tolerate the drug. NCCN and ESMO guidelines frame it simply as until progression or unacceptable toxicity. Some people are on sunitinib for less than a year; others continue for several years. Your oncologist can tell you what median durations looked like in the trials relevant to your cancer type, which gives a rough reference without being a personal prediction.

A short, planned break is sometimes possible. Sunitinib already builds in two weeks off per cycle, which may be enough to plan around. If you need a longer pause — for surgery, another procedure, or a significant family commitment — tell your oncologist well in advance. They will weigh the timing against where you are in your cycle and what your recent scans showed. Do not stop the drug on your own without telling your team first.

Often yes. A dose reduction or a temporary stop to let side effects settle is a recognised part of managing sunitinib, and many people restart at a lower dose or on the 2/1 schedule. Whether restarting makes sense depends on why you stopped and what the cancer was doing at that point. Stopping for toxicity is not the same as the drug failing — your oncologist will assess both before making a recommendation.

Not necessarily. Staying on it longer means it has continued to control the cancer, which is a good sign, but duration reflects the biology of your tumour rather than the drug doing more work over time. Some cancers remain stable on sunitinib for a long time; others progress sooner. What matters at each review is what your scans show, not how many cycles you have completed.

There are established second-line options. For kidney cancer, NCCN guidelines list several targeted agents and immunotherapy combinations as options after sunitinib. Which one your team recommends depends on your performance status, the side effects you experienced, and what the cancer is doing at progression. Sunitinib stopping working means the first-line option has been exhausted — it does not mean treatment has run out.

Usually through your scheduled imaging — a CT or PET-CT scan every two to three cycles that measures the cancer's size and spread. If scans show the cancer has grown, your team will say the disease has progressed. Sometimes new or worsening symptoms prompt an earlier scan. You may not feel a difference between stable disease and slow progression, which is exactly why the scan schedule matters and why a missed appointment should be flagged to your team promptly.